Is the Rally in Cannabis Stocks Officially Over?

Here’s why growth investors looking at top cannabis stocks may want to re-think their thesis as we head into what could be a volatile year.

| More on:
edit Jars of marijuana

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Cannabis stocks remain among the top equities for investors looking for big wins in 2022. It’s expected that the marijuana industry is likely to double in terms of its valuation within 2025. For those seeking immense growth and innovation, the cannabis sector remains an exciting place to invest.

That said, the rallies we’ve seen in 2017 and 2019 have fizzled out in a big way. Investors looking for growth have seemingly sought out other high-growth sectors.

Is the cannabis sector officially on the out with investors? Or can this sector roar back this year?

Let’s take a look.

Massive jump in M&A activity hasn’t boosted sales like investors expected

Last year marked one of the biggest years for M&A activity in the cannabis sector. Many of the largest cannabis producers sought out smaller targets, acquiring their way toward expanded market share. These moves were made in a bid to boost revenues and show top-line growth.

Unfortunately for many producers, this hasn’t quite been the case.

Some cannabis giants are actually seeing revenue declines, as demand fails to materialize as expected. Yes, year-over-year growth in overall cannabis consumption remains high. However, in Canada, a large black market continues to plague legal producers — something regulators had hoped wouldn’t be the case.

Whether it’s a result of the relatively high tax rate on cannabis in Canada, or other factors such as quality, selection, and packaging restrictions, many consumers have chosen to stick with their dealer.

For Canadian cannabis producers, this has resulted in relatively poor results of late. Canopy Growth witnessed steady shrinkage in its revenue for the third consecutive quarter. 

Quebec-based Hexo (TSX:HEXO)(NASDAQ:HEXO) invested over $700 million to purchase three cannabis producers – Redecan, Zenabis Global, and 48North Cannabis Corp. But it announced it was shutting down the facilities of 48North barely eight weeks after the acquisition. It also announced the closing of one of the production facilities of Zenabis as well.

Additionally, Aurora Cannabis saw sales decline 7.2% on a year-over-year basis.

Where should investors go from here?

The recent results posted by top cannabis producers certainly don’t signal a heck of a lot of near-term growth potential. Some experts believe that fast-changing consumer preferences are partly to do with this trend. However, as noted, the incredibly high regulatory bar placed on this sector in Canada is likely stifling consumer confidence in the legal cannabis sector.

For investors looking for buying opportunities in this space, valuations are certainly much more attractive today. Perhaps now is the time to buy, when no one else is considering this sector. That said, with a lack of catalysts, it’s hard to point to what driver may take these cannabis stocks higher any time soon.

For now, I’m sitting tight on the cannabis sector. I think much of the M&A activity that has been carried out over the past five years has been at valuations that did not make sense. Accordingly, I think more writedowns (and more stock price volatility) are likely to be the common theme for 2022.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Chris MacDonald has no position in any of the stocks mentioned. The Motley Fool recommends HEXO Corp.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »